Immunoglobulin G1, Anti-(Human Cd Antigen Cd27) (Human Monoclonal Cdx-1127 Clone 1F5 Heavy Chain), Disulfide With Human Monoclonal Cdx-1127 Clone 1F5 .Kappa.-Chain, Dimer
Distal Biliary Tract Carcinoma
Explore 6 assets in Distal Biliary Tract Carcinoma →Floatz Rating
CC44/100
Confidence
Indicative
Sponsor
National Cancer Institute (NCI)
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
29Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04941287CT.gov Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Distal Biliary Tract Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Immunoglobulin G1, Anti-(Human Cd Antigen Cd27) (Human Monoclonal Cdx-1127 Clone 1F5 Heavy Chain), Disulfide With Human Monoclonal Cdx-1127 Clone 1F5 .Kappa.-Chain, Dimer (this asset) | National Cancer Institute (NCI) | P2 | CC · 44 |
| Capecitabine | National Cancer Institute (NCI) | P2 | B |
| Fluorouracilum | National Cancer Institute (NCI) | P2 | B |
| Trametinib | National Cancer Institute (NCI) | P2 | B |
| mk-2206 | National Cancer Institute (NCI) | P2 | CCC |
| Cobimetinib | National Cancer Institute (NCI) | P2 | CCC |
| Pantoprazole | Washington University School of Medicine | P2 | CCC |
| Atezolizumab | National Cancer Institute (NCI) | P2 | CCC |
| Cis-Diamminedichloroplatinum Ii | National Cancer Institute (NCI) | P1 | CC |
+1 more in the Distal Biliary Tract Carcinoma cohort
Other indications for Immunoglobulin G1, Anti-(Human Cd Antigen Cd27) (Human Monoclonal Cdx-1127 Clone 1F5 Heavy Chain), Disulfide With Human Monoclonal Cdx-1127 Clone 1F5 .Kappa.-Chain, Dimer
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| B-Cell Non-Hodgkin Lymphoma | — | P2 | CCC · 51 |
| Melanoma | — | P2 | CCC · 49 |
| Burkitt Lymphoma | — | P2 | CCC · 48 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Immunoglobulin G1, Anti-(Human Cd Antigen Cd27) (Human Monoclonal Cdx-1127 Clone 1F5 Heavy Chain), Disulfide With Human Monoclonal Cdx-1127 Clone 1F5 .Kappa.-Chain, Dimer in Distal Biliary Tract Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/immunoglobulin-g1-anti-human-cd-antigen-cd27-human-monoclonal-cdx-1127-clone-1f5-heavy-chain-disulfide-with-human-monoclonal-cdx-1127-clone-1f5-kappa-chain-dimer-distal-biliary-tract-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →